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Myocardialund receptor that mediates signals derived from class 3 secreted semaphorins.
Although semaphorin signaling in axon guidance in the nervous system has been extensively studied,
functions outside the nervous system including important roles in vascular patterning have also been
demonstrated. Inactivation of plexinD1 leads to neo-natal lethality, structural defects of the cardiac outﬂow
tract, peripheral vascular abnormalities, and axial skeletal morphogenesis defects. PlexinD1 is expressed by
vascular endothelial cells, but additional domains of expression have also been demonstrated including in
lymphocytes, osteoblasts, neural crest and the central nervous system. Hence, the cell-type speciﬁc functions
of plexinD1 have remained unclear. Here, we describe the results of tissue-speciﬁc gene inactivation of
plexinD1 in Tie2 expressing precursors, which recapitulates the null phenotype with respect to congenital
heart, vascular, and skeletal abnormalities resulting in neonatal lethality. Interestingly, these mutants also
have myocardial defects not previously reported. In addition, we demonstrate functions for plexinD1 in post-
natal retinal vasculogenesis and adult angiogenesis through the use of inducible cre-mediated deletion.
These results demonstrate an important role for PlexinD1 in embryonic and adult vasculature.
© 2008 Elsevier Inc. All rights reserved.Introduction
In the central nervous system semaphorins promote axon
guidance by mediating both attractive and repulsive cues (Dickson,
2002; Raper, 2000; Tessier-Lavigne, 2002; Tessier-Lavigne and Good-
man, 1996; Tran et al., 2007). There are ﬁve vertebrate classes of
semaphorins (classes 3–7) which can be either membrane bound or
secreted (Fujisawa and Kitsukawa, 1998), and a wide variety of
mammalian family members, domains of expression and receptor
binding speciﬁcities contribute to the complexity of neuronal
patterning and development. Most semaphorins bind to plexin
receptors that transduce signals, and some class 3 secreted semapho-
rins bind to receptor complexes composed of plexin and neuropilin
subunits (Tamagnone and Comoglio, 2000).
In recent years, functions for semaphorins and their receptors have
been identiﬁed in the developing vasculature that are in many waysevelopmental Biology, Cardio-
hia, PA 19104, USA. Fax: +1 215
pstein).
l rights reserved.analogous to those described in the central nervous system (Autiero
et al., 2005; Carmeliet and Tessier-Lavigne, 2005; Eichmann et al.,
2005; Suchting et al., 2006). For example, neuropilins are expressed by
vascular endothelial cells, where they heterodimerize with tyrosine
kinase receptor subunits to compose receptors for heparin-binding
isoforms of vascular endothelial growth factor (VEGF) (Neufeld et al.,
2002a,b). Semaphorins can modulate the migratory and growth
characteristics of cultured endothelial cells, in part by competing
with VEGF for neuropilin-containing receptors, but also by binding to
receptors that do not recognize VEGF (Banu et al., 2006; Basile et al.,
2005; Catalano et al., 2004; Gu et al., 2005; Guttmann-Raviv et al.,
2007; Toyofuku et al., 2007). For example, Sema3E can function as a
regulator of angiogenesis and vascular pathﬁnding in vivo by binding
directly to plexinD1 on endothelial cells (Gu et al., 2005). PlexinD1 can
mediate repulsive guidance cues in the vasculature, thus contributing
to the formation of the complex but largely predictable vascular
network that accompanies embryonic development (Carmeliet and
Tessier-Lavigne, 2005; Eichmann et al., 2005). Other families of axon
guidance molecules have also been implicated in vascular patterning,
including the Slit/Robo, Ephrin/Eph and Netrin/Unc5 networks,
suggesting signiﬁcant parallels between the neuronal and vascular
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Eichmann et al., 2005; Suchting et al., 2006).
The discovery that semaphorin, plexin and neuropilin signaling
affect vascular growth has important implications for the deve-
lopment of novel pro- or anti-angiogenic therapies. For example,
Sema3F displays anti-angiogenic activities in animal models of cancer
(Kessler et al., 2004), although the receptor complex that mediatesFig. 1. PlexinD1 is broadly expressed in late embryonic development and is required for Sema
hybridization (red signal) in the heart and vascular endothelium (A, arrowhead), forebrain (C
ossiﬁcation centers of vertebral bodies (J, arrowhead). Adjacent sections were stained for vW
andwnt2 by in situ hybridization (I). fb, fore brain; gV, trigeminal ganglion; cp, choroid plexu
500 μm in panel C and 100 μm in other panels. (K) Boyden chamber assays reveal the motility
calcein AM emission (see Materials and methods). PECs from plexinD1+/− (het, dotted line)
soluble Sema3Awas added to the upper chamber (3A). (L) Aortic ring assays reveal reduced r
complete medium (green) or complete medium plus Sema3A (red). Results are expressed as
SEMA3A conditional medium) from wild type and plexinD1+/− explants (n=10). From plexinD
1.23±0.17 mm (in SEMA3A conditional medium). Representative images of aortic ring explathis effect is unclear. PlexinD1, which can bind to class 3 semaphorins,
is up-regulated in the tumor vasculature of some mouse models of
cancer and can be targeted with intravenous injection of monoclonal
antibodies directed against PlexinD1 (Roodink et al., 2005). Sema-
phorins also have direct effects on the migration and proliferation of
some tumor cells (Guttmann-Raviv et al., 2007; Neufeld et al., 2005).
Therefore, tissue-speciﬁc gene inactivation of semaphorins and their3A-mediated endothelial cell migration in vitro. PlexinD1mRNAwas detected by in situ
), dorsal root ganglia and adrenal gland (D, arrowhead), lung mesenchyme (G), and the
F (B, H), neuroﬁlament (2H3) (E) and tyrosine hydroxylase (F) by immunohistochemistry
s; ad, adrenal gland; drg, dorsal root ganglion; oc, ossiﬁcation center. Scale bars equal to
of primary endothelial cells (PEC) from plexinD1−/−mouse is impaired as determined by
and plexinD1−/− (ko, solid line) pups were assessed at basal condition (Ctrl), and when
esponsiveness of plexinD1−/− aortic explants to Sema3A. The explants were incubated in
absolute outgrowth in mm: 1.26±0.19 mm (in control medium), and 1.02±0.18 mm (in
1−/− explants (n=7), the absolute outgrowth is 1.17±0.13 mm (in control medium) and
nts are shown in Fig. S1. n.s., not signiﬁcant.
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various cancer models.
We (Gitler et al., 2004b; Torres-Vazquez et al., 2004) and others
(Gu et al., 2005; van der Zwaag et al., 2002) have previously shown
that plexinD1 is expressed in the developing vasculature. In zebraﬁsh,
expression is similar to that of ﬂi1 in the endothelial compartment,
and mutations in zplexinD1 results in the out of bounds phenotype in
which intersomitic blood vessels migrate inappropriately into
domains where class 3 semaphorins are expressed (Torres-Vazquez
et al., 2004). In mice, plexinD1 expression is prominent in developing
endothelial cells throughout the vasculature, but expression is also
apparent in the central nervous system (Gu et al., 2005; van der Zwaag
et al., 2002), in the salivary gland (Chung et al., 2007), neural crest
(Toyofuku et al., 2008) and in bone (Kanda et al., 2007). Analysis of
the GEO database (Gene Expression Omnibus, http://www.ncbi.nlm.
nih.gov/geo/) suggests additional sites of expression including
lymphocytes.Fig. 2. Targeted disruption of plexinD1. (A) A schematic illustration of the plexinD1 locus, targe
probe as shown in Panel A was used for Southern blot analysis to detect heterozygous recom
conﬁrms germline transmission. The 580 bp band represents the wild-type allele, while the 6
endothelium of E12.5 D1ECKO embryos (G-I) is demonstrated by in situ hybridization, while
and the smooth muscle of the small intestine (double arrow). The D1ECKO embryo has persiHomozygous deﬁciency of plexinD1 in mice leads to neo-natal
lethality with a high penetrance of a severe form of congenital heart
disease (Gitler et al., 2004b) in addition to more subtle peripheral
vascular patterning defects (Gitler et al., 2004b; Gu et al., 2005). The
congenital heart defects involve the outﬂow tract of the heart, which
normally arises as a single tube, the truncus arteriosus, and later
septates into twomajor vessels, the aorta and the pulmonary artery. In
plexinD1 mutants, this septation process fails to occur and mice are
bornwith a persistent truncus arteriosus and other patterning defects
of the aortic arch arteries (Gitler et al., 2004b). Septation of the cardiac
outﬂow tract is known to be critically dependent upon cardiac neural
crest cells, which migrate from the dorsal neural tube and contribute
to the deﬁnitive aortico-pulmonary septum and the tunica media of
the great vessels (Engleka et al., 2005; Epstein et al., 2000; Gitler et al.,
2002; Kirby et al., 1983). Interestingly, inactivation of Sema3C, a class 3
semaphorin that is able to bind to PlexinD1, also results in cardiac
outﬂow tract defects (Brown et al., 2001; Feiner et al., 2001). PlexinD1ting vector, and the targeted locus after Flp-mediated recombination. (B) The 5′ external
binants using BglII-digested genomic DNA. (C) PCR of tail DNA from plexinD1ﬂox/+ mice
20 bp band indicates the targeted allele. (D–I) Absence of plexinD1mRNA in the vascular
plexinD1 transcripts are detected in other tissues including trigeminal ganglion (arrow)
stent truncus arteriosus (D). A, aorta. P, pulmonary artery. TA, truncus arteriosus.
Table 1
Genotypes resulting from Tie2-cre, plexinD1+/− X plexinD1ﬂox/+ matings
E11.5–E18.5 P0–P1 P2–P4
Obsa %Obsb %Expc Obs %Obs %Exp Obs %Obs %Exp
plexinD1+/+ 8 16 12.5 17 15 12.5 9 12 12.5
plexinD1ﬂox/+ 6 12 12.5 13 11 12.5 14 18 12.5
plexinD1+/− 8 16 12.5 10 9 12.5 13 17 12.5
plexinD1ﬂox/− 3 6 12.5 15 13 12.5 13 17 12.5
Tie2cre, plexinD1+/+ 9 18 12.5 14 12 12.5 4 5 12.5
Tie2cre, plexinD1ﬂox/+ 7 14 12.5 19 16 12.5 15 19 12.5
Tie2cre, plexinD1+/− 4 8 12.5 14 12 12.5 10 13 12.5
Tie2cre, plexinD1ﬂox/− 6 12 12.5 13 11 12.5 0 0 12.5
Total 51 115 78
a The number of mice observed (Obs) for each genotype is recorded.
b The percent of mice observed (%Obs) for each genotype is recorded.
c The percent of mice expected (%Exp) if Mendelian ratios were obtained is indicated.
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and a functional role for plexinD1 in neural crest precursors in
addition to a potential role in endothelium could have explained the
congenital cardiac defects present in the null mice. PlexinD1 deﬁcient
mice also display axial skeletal abnormalities involving the vertebral
bodies, ribs and cartilage, and plexinD1 is expressed by osteoblasts
(Kanda et al., 2007).
In order to determine the tissue-speciﬁc functions of plexinD1
that account for the phenotypes that have been described in
homozygous null mice, we have created a new allele of plexinD1 in
which critical exons are ﬂanked by loxP sites allowing for cre-
mediated tissue- and temporal-speciﬁc inactivation. We show that
loss of function of plexinD1 in neural crest is well tolerated. In
contrast, loss of plexinD1 function in cells derived from Tie2-
expressing precursors recapitulates the congenital heart, vascular
and skeletal defects observed after ubiquitous loss of function.
Furthermore, inducible deletion after birth demonstrates functions
for plexinD1 in postnatal retinal vasculature.
Results
PlexinD1 is expressed in the vasculature and other tissues
We examined the expression domain of plexinD1 RNA by
performing in situ hybridization analysis on E9.5, E12.5, E14.5, E16.5
and E18.5 wild type embryos. At early embryonic stages from E9.5 to
E12.5, plexinD1 is expressed in the endothelium and central nervous
system (CNS) as has been previously published (Gitler et al., 2004b; Gu
et al., 2005; van der Zwaag et al., 2002). From E14.5 to E18.5, plexinD1
expression continues to be robust in the endocardium and vascular
endothelium (Fig. 1A), and also becomes evident in the brain
(forebrain, trigeminal ganglion and choroids plexus, Fig. 1C), dorsal
root ganglion, adrenal gland, kidney, lung mesenchyme, ossiﬁcation
center of the bones and small intestine (Figs. 1D, G, J and 2F). To verify
the tissue types where the expression was observed, we stained
adjacent sections for expression of von Willebrand factor (vWF),
which is speciﬁc for vascular endothelial cells, the neuronal tissue
marker neuroﬁlament (2H3), the adrenergic neuron marker tyrosine
hydroxylase (TH) and the lung mesenchyme marker wnt2. The
previously unappreciated broad expression pattern during late
gestation of plexinD1 prompted us to re-consider the cause of the
perinatal death of plexinD1 null mice and to rigorously examine the
cell-autonomous role for plexinD1 in endothelium.
PlexinD1 modulates primary endothelial cell migration in vitro
We performed Boyden chamber migration assays to study the
motility of plexinD1-deﬁcient primary endothelial cells. Endothelial
cells were harvested from plexinD1+/− and plexinD1−/− P0 neonates
using CD31-antibody selection and seeded in the upper chamber.
After various times of incubation, the number of the cells that
migrated through the membrane was determined in the presence or
absence of Sema3A. PlexinD1−/− cells migrate less robustly than control
cells either in the presence of growth factors, and they failed to
respond to Sema3A (Fig. 1K).
We also performed aortic ring assays to investigate endothelial cell
migration using control and plexinD1−/− aortic explants. In this assay,
endothelial cells migrate from the aortic explants into the gel matrix
and form vascular branches (Masson et al., 2002) (Fig. S1). We
quantiﬁed the absolute outgrowth distances from control and plex-
inD1−/− explants in the absence or presence of Sema3A. Outgrowth
distance was signiﬁcantly inhibited by Sema3Awhen control explants
were used, but Sema3A did not affect plexinD1−/− explants (Fig. 1L).
Thus, endothelial cells lacking PlexinD1 display abnormal migratory
characteristics consistent with a cell-autonomous role for PlexinD1 in
endothelial cells.Inactivation of plexinD1 in Tie2-derivatives results in
cardiovascular defects
To delete plexinD1 in a tissue-speciﬁc manner, we generated a
ﬂoxed allele of plexinD1 in the mouse. The ﬁrst exon of plexinD1,
containing the translational start codon and part of the SEMA domain,
was ﬂanked by loxP sites. Correctly targeted ES cells were identiﬁed by
Southern blot analysis (Figs. 2A, B) and used to create chimeric mice
and germline heterozygotes after removal of the frt-ﬂanked PGK-neo
cassette. Germline transmission and genotyping was conﬁrmed by
PCR (Fig. 2C).
We crossed plexinD1ﬂox/+ mice with Tie2-cre mice in order to
inactivate plexinD1 in the endothelial compartment. (Hereafter, we
refer to Tie2-cre; plexinD1ﬂox/− and Tie2-cre; plexinD1ﬂox/ﬂox mice as
D1ECKO mice). Tie2-cre mice have been extensively characterized and
efﬁciently mediate endothelial recombination in appropriate reporter
mice beginning at E9.5 (Constien et al., 2001; de Lange et al., 2004;
Kisanuki et al., 2001). In situ hybridization with a plexinD1-speciﬁc
riboprobe using E12.5 embryo sections showed complete deletion of
plexinD1 in the vascular endothelium in D1ECKO mice compared to
controls, while plexinD1 mRNA expression remained evident non-
endothelial cells (Figs. 2D–I).
Genotype data from Tie2-cre, plexinD1+/− X plexinD1ﬂox/+ matings
are shown in Table 1. Notably, we were unable to identify D1ECKO mice
after the ﬁrst day of life, while other genotypes were found at close to
expected ratios. We performedmore matings than shown in Table 1 in
order to produce embryos for all the studies shown and for each
experiment, N is greater to or equal to 4. At birth (P0) D1ECKO pups
were identiﬁed, but nearly uniformly appeared cyanotic and
succumbed by P1. Mutant pups had shorter stature and tail length
(Fig. 3A). Subcutaneous hemorrhage, especially in the head, was
routinely apparent and allowed for prompt identiﬁcation of mutant
pups (Fig. 3B). D1ECKO mice displayed severe cardiac defects. At birth,
wild type hearts are characterized by a fully septated outﬂow tract
with a distinct aorta and pulmonary artery (Fig. 3C). D1ECKO mutant
hearts showed persistent truncus arteriosus in the majority of cases
(Fig. 3D). In some cases, partial septation was evident, although the
outﬂow tract was malrotated and a right-sided aortic arch was
sometimes present (Figs. 3E, F). The coronary arteries, which normally
originate from the root of the aorta, were instead noted to originate
more distally from the ascending portion of the truncus arteriosus, or
from the ascending aorta (when partial or compete septation was
present) in all mutant hearts examined (N=5) (Figs. 3D–F), and
multiple small hemorrhages were apparent on the ventricular walls.
The atria were markedly dilated and abnormal with a “raspberry-like”
appearance (Figs. 3D, E). Histological sections of mutant hearts
revealed ventricular septal defects and abnormally condensed and
discontinuous atrial myocardial architecture when compared to
controls (Figs. 3G, H).
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accounts for cardiac defects in plexinD1 null mice. However, cardiac
outlﬂow tract defects, including truncus arteriosus, are commonly
associated with neural crest abnormalities (Stoller and Epstein, 2005),
and plexinD1 expression in cardiac neural crest has been reported
(Toyofuku et al., 2008). Nevertheless, we found that neural crest-
speciﬁc deletion of plexinD1 using Wnt1-cre resulted in normal
appearing and viable mice without congenital cardiac defects such as
those seen in plexinD1 null pups. We obtained 241 P0–P3 pups from
Wnt1-cre, plexinD1ﬂox/+ X plexinD1+/− matings, of which 37 (15%) were
Wnt1-cre, plexinD1ﬂox/− (compared to 12.5% expected) and outﬂow
tract septation was normal (Fig. S2).
In addition to structural heart, coronary and atrial defects, D1ECKO
embryos also displayed peripheral vascular defects. Whole-
mount PECAM antibody staining of E11.5 embryos revealed immatureFig. 3. D1ECKO mice were born alive but died within 2 days and displayed cardiac and vasculat
(arrows). (B) Hemorrhage is present in the head region ofD1ECKO at P0 (arrows). (C–F) Hearts f
some animals, while others show septationwith abnormal patterning of the aorta (Ao) and pu
and hemorrhages on the ventricular walls (arrowheads, D, E). (G, H) H and E staining of P0 hea
from the epicardium in mutants (arrowhead, H). Some mutant hearts also displayed ventricu
and D1ECKO embryos. LV, left ventricle; RV, right ventricle; A, atrium.intersomitic vessels with poorly remodeled vascular plexus (Figs. 3I, J).
At this time point, aortic outﬂow and atrial defects were already
evident by routine histology (Figs. 4A, B). The atrial myocardium of the
D1ECKO hearts was condensed, discontinuous and separated from
the epicardium (Figs. 4C, D). The ventricular myocardial wall was
abnormal and unusual epicardial blood islands were present (Figs.
4E, F). We used Foxp4 andMF20 as epicardial andmyocardial markers,
respectively, at this embryonic stage. Foxp4 has been shown to
express in the mouse epicardium from E9.5 to E12.5 (Li et al., 2004)
and MF20 recognizes myosin and MF20 recognizes myosin. Coronary
vessel defects were evident by E12.5 as detected by whole-mount
PECAM staining (Figs. 4G–J). Interestingly, the mutant conotruncus
was surrounded by PECAM positive cells (arrow, Fig. 4H), which are
normally not present in this location at this developmental stage, as
shown in the wild type control (Fig. 4G). It is interesting to note thature defects. (A) P0 D1ECKO pups have shorter statues and tails thanwild type litter mates
romwild type (C) andD1ECKO (D–F) P0 pups reveal persistent truncus arteriosus (TA, D) in
lmonary artery (P) (E, F). All mutants pups had abnormal coronary origins (arrows, D, E)
rt sections shows condensed and discontinuous atrial myocardiumwhichwas separated
lar septal defects (arrowhead, H). (I, J) Whole-mount PECAM staining of E11.5 wild type
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(Brown et al., 2001). Abnormal clusters of PECAM-positive cells were
apparent on the ventricular surface of the mutant hearts (Fig. 4J),
consistent with abnormal coronary vessel formation.Fig. 4. Cardiovascular defects in D1ECKO embryos are evident at mid-gestation. (A, B) H
and E staining of cross sections from control and D1ECKO E11.5 hearts shows condensed
and discontinuous atrial myocardium in the mutant (B, arrow), which also displays
truncus arteriosus (TA), while the aorta (Ao) and pulmonary artery (P) are separated in
the Tie2-cre control heart (A). (C, D) Sections adjacent to those shown in (A, B) were
stained for Foxp4 (green) and MF20 (red), markers of epicardium and myocardium,
respectively. (E, F) H and E stained sections of ventricular regions show abnormal blood
islands in D1ECKO embryos (arrows) and abnormal thickened regions of compact
myocardium (brackets). (G, H) Whole-mount PECAM staining of E12.5 wild type (WT)
and D1ECKO hearts shows coronary vessel plexus defects in mutants (H). The base of the
outﬂow trunk in the D1ECKO embryo is covered with PECAM-positive cells (arrow, H),
while the corresponding region of the wild type is not (arrow, G). (I, J) Higher
magniﬁcation of the boxes in (G) and (H), showing large clusters of PECAM positive cells
are apparent in the ventricular surface of the D1ECKO heart (arrowheads, J). Scale bars
equal to 50 μm in panels A, B, E, F and 100 μm in panels C, D.Tie2-cre inactivation of plexinD1 results in skeletal defects
Previous research has shown that plexinD1−/− mice have skeletal
defects (Kanda et al., 2007). To determine if the skeletal abnormalities
are due to a primary bone defect or are secondary to vascular defects,
we analyzed bone formation in the D1ECKO mice. Interestingly, D1ECKO
mice display skeletal defects indistinguishable from those seen in
plexinD1−/− mice at birth, as revealed by Alizarin Red S and Alcian Blue
staining. In both plexinD1−/− and D1ECKO P0 pups, the vertebral bodies
were poorly formed and frequently fused or split in both thoracic
(Figs. 5A–C) and lumbar regions (Figs. 5D–F). Staining for vWF to
identify endothelial cells revealed abnormal microvasculature within
bones derived from plexinD1−/− and D1ECKO mice when compared to
controls, though large vessels attached to the long bones appeared
intact (Figs. 5G–I). Surprisingly, one D1ECKO mouse survived to
adulthood, perhaps because of relatively inefﬁcient cre-mediated
recombination in this case. We performed μ-CT imaging to examine
skeletal structures, which revealed multiple vertebral body fusions
along the entire anterior–posterior axis (Figs. 5J–K).
We sought to determine if skeletal defects were related to activity
of Tie2-cre in bone lineages as opposed to vascular endothelial cells.
We harvested primary osteoblasts from plexinD1ﬂox/− and D1ECKO P0
pups and examined plexinD1mRNA levels by quantitative RT-PCR. No
signiﬁcant loss of plexinD1 mRNA was detected in the osteoblast
culture from D1ECKO samples (data not shown). Lineage tracing of
Tie2-cre derivatives in Tie2-cre, Z/EG embryos shows that Tie2-cre
derivatives are not detectable in bony structures at E14.5, prior to
vascularization (Figs. S3A, B). These results are consistent with prior
data which indicate that the Tie2 promoter is not active in osteoblasts
(Winslow et al., 2006). However, Tie2-cre is active in osteoclast
progenitors (Wan et al., 2007) which ﬁrst invade developing bone at
E15.5. At this time point, we already detected signiﬁcant skeletal
abnormalities, including rib fusions (Figs. S3C, D). Therefore, we
believe that skeletal defects in plexinD1 null mice are most likely
secondary to vascular abnormalities and are unlikely to be related to
loss of plexinD1 in bone lineages, although a role for plexinD1 in
osteoclasts cannot be completely ruled out.
Post-natal inducible deletion of plexinD1 produces post-natal defects
of angiogenesis
In order to bypass neo-natal lethality and to study the function of
PlexinD1 in post-natal mice, we crossed plexinD1ﬂox/+ mice with
tamoxifen-inducible CMV-creER mice (Hayashi and McMahon, 2002)
to produce CMV-creER, plexinD1ﬂox/ﬂox newborns. (We henceforth
refer to CMV-creER, plexinD1ﬂox/ﬂox and CMV-creER, plexinD1ﬂox/−mice
as D1CMV-ERKO). Nuclear translocation and subsequent cre recombi-
nase activity was induced by intraperitoneal injection of tamoxifen on
each of 2 successive days, and 92% loss of plexinD1 mRNA expression
was conﬁrmed by quantitative RT-PCR (Fig. 6A). Tamoxifen was
injected on P3 and P4 and retinal blood vessel development was
assessed by FITC-dextran injection and confocal microscopy at P10
(Figs. 6B–I). Loss of PlexinD1 resulted in severe retinal vasculature
defects, including lack of retinal vessel development in the deeper
layers of the retina (Fig. 6C), and vessel leakage and hemorrhage
(Figs. 6D–I). We have not identiﬁed other postnatal angiogenic defects
in PlexinD1 knockout mice to date.
In a separate set of experiments, tamoxifen or vehicle was
administered at 6 weeks of age and matrigel plugs were implanted
subcutaneously. After 7 days, the animals were sacriﬁced and vascular
inﬁltration of the matrigel plugs was assessed by Masson's trichrome
staining (Fig. S4A). Deletion of plexinD1 resulted in a marked decrease
in the number and extent of endothelial cell migration into the plugs.
Under basal conditions when the growth-factor reduced matrigel
alone was implanted, slightly fewer numbers of cells invaded the plug
in the D1CMV-ERKOmice compared to the control.When endothelial cell
Fig. 5. Tie2-cre inactivation of plexinD1 results in skeletal defects. (A–F) Alizarin Red S and Alcian Blue Staining of P0 pup thoracic (A–C) and lumbar (D–F) skeletons. Both plexinD1−/−
and D1ECKO pups revealed axial skeletal malformations, including fusions and splitting (circles and arrows, B, C, E, F) of the vertebral bodies. (G–I) vWF (green) staining of wild type,
plexinD1−/− and D1ECKO P0 sections of bone reveal fewer vWF-positive microvascular cells in both plexinD1−/− (H) and D1ECKO (I) samples compared to control (arrows, G). Insets show
intact vWF staining from the large epichondrial vessels invading adjacent bone in all three animals. (J, K) Control (J) and D1ECKO (K) 3-dimensional reconstruction from μ-CT imaging
in which structures are viewed from the left, posterior aspect reveal fusion of multiple vertebrae in the D1ECKO animal (green arrows, K) that are not seen in the control (J).
88 Y. Zhang et al. / Developmental Biology 325 (2009) 82–93growth factors (ECGF) were added to the matrigel plug, there was a
signiﬁcant increase in cell inﬁltration in the control animals, but in the
D1CMV-ERKO animals, the cell numbers remained at basal level,
suggesting a signiﬁcant defect in post-natal angiogenesis (Fig. S4B).
Discussion
Although plexinD1 expression is not restricted to endothelium,
inactivation of plexinD1 in Tie2-expressing cells is sufﬁcient to
recapitulate the phenotypes previously observed in plexinD1 null
pups including perinatal lethality, congenital heart, coronary vessel,
peripheral vasculature and skeletal defects. Additionally, inducible
deletion of plexinD1 in post-natal mice produces angiogenic defects in
the retina and in matrigel plug assays.
The most likely explanation for the phenotypes that we describe in
D1ECKO mice is that plexinD1 function in endothelial cells is requiredfor cardiovascular development and neonatal viability, and that this
activity is removed by Tie2-cre mediated inactivation. However,
because Tie2-cre also mediates recombination in hematopoietic
precursors (Gitler et al., 2004a; Schlaeger et al., 2005), we cannot
formally exclude a critical function for plexinD1 in blood. Alternative
endothelial cre mice exist, such as VE-cadherin-cre (Alva et al., 2006;
Monvoisin et al., 2006), but in our experience efﬁciency has been far
less robust than with Tie2-cre during development. Furthermore, we
have not observed plexinD1 expression in blood lineages in the
embryo. Hence, we interpret our results to strongly implicate loss of
plexinD1 function in endothelium as the cause of neo-natal lethality
and pathology in D1ECKO mutants.
Interestingly, D1ECKO mouse embryos also have myocardial defects
not previously described. Myocardial development is known to
depend upon signals from endocardium. For example, neuregulin-1
is expressed exclusively in the endocardium and provides paracrine
Fig. 6. PlexinD1 functions in postnatal angiogenesis. (A) Quantitative PCR of retina shows effective deletion of plexinD1 after tamoxifen treatment in D1CMV-ERKO mice compared to
control (CTRL). The relative expression of PlexinD1 is 0.08±0.04 fold of the control. (n=3) (B) Confocal images pseudocolored to indicate depth of vascular structures in retinal
ﬂatmounts from a control P10 pup reveals 2 layers of retinal vessels (green = top layer, 24 μm depth; red = bottom layer, 28.5 μm depth). (C) Confocal image of a D1CMV-ERKO P10 pup
shows only one layer of vessels on the surface of retina with fewer deep vessels. (D–F) FITC-dextran perfusion of control (D) and mutant (E, F) retina samples reveals vascular leakage
in mutants both from large vessels (E) and from smaller vascular plexi at the periphery of the retina (F). Scale bar equals to 50 μm. (G–I) Confocal images of control (G) and mutant
(H, I) retina ﬂat mounts show hemorrhage on the retina surface (H), and in the deep layer (I) of mutants.
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myocardial cells, to orchestrate proper ventricle trabeculation (Meyer
et al., 1997). Similarly, depleting myocardial angiopoietin-1 resulted in
defects both in the endocardial monolayer and adjacent myocardial
trabeculation (Suri et al., 1996). Our data suggest that loss of plexinD1
in endocardium affects myocardial development, perhaps by affecting
cell–cell contacts or paracrine substances produced by endothelial
cells that modulate myocardial development. Future studies will
address the molecular nature of these signals.
The observation of skeletal defects in D1ECKO mice was surprising,
given the prior description of plexinD1 expression in osteoblasts and
the suggestion that this might account for the skeletal abnormalities
(Kanda et al., 2007). We conﬁrmed that Tie2-cre was not active in
osteoblast precursors and that osteoblast expression of plexinD1 was
retained in D1ECKO pups. Tie2-cre is active in precursors of osteoclasts,
which function in bone resorption (Wan et al., 2007). Osteoclasts are
multinucleated cells that enter the bone through blood vessels, ﬁrst
appearing in skeletal structures at E15.5 (Kahn and Simmons, 1975;
Manolagas and Jilka, 1995). Osteoclast defects result in osteoporosis(when there is too much osteoclast activity), and osteopetrosis (when
osteoclast activity is deﬁcient) (Helfrich, 2003; Tondravi et al., 1997).
We are unaware of any data that would link osteoclast abnormalities
to vertebral body morphology defects such as those in D1ECKO mice.
Furthermore, we have detected bone defects prior to osteoclast
mediated bone resorption (Fig. S3). Also, prior studies have indicated
that bone mineral density of plexinD1 knockout newborns is not
altered (Kanda et al., 2007), suggesting that osteoclast activity is
unaffected. Thus, it is likely that endothelial-related vascular defects
account for the skeletal abnormalities that we observe, and this is
consistent with alterations in vWF expression and microvascular
patterning in bone of mutant mice. These axial patterning defects,
characterized by hemivertebrae and vertebral fusions, are reminiscent
of spondylothoracic and spondylocostal dysostosis (SCDO1) in human
patients which can be caused by mutations in the Notch ligand
encoded by DLL3 (Bulman et al., 2000). The Notch-Delta pathway
plays an important role in the “segmentation clock” that patterns the
presomitic mesoderm and forming somites which give rise to skeletal
derivatives (Dunwoodie et al., 2002). Therefore, we examined
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somite and sclerotome patterning, but did not observe differences in
D1ECKO embryos compared to controls (Figs. S3E, F and data not
shown).We did note abnormalities of intersomitic vascular patterning
as early as E11.5 (Figs. 3I, J) and subtle defects of somite polarity,
morphology or gene expression associated with these vascular
patterning defects that were below our level of detection cannot be
ruled out, and could be signiﬁcant contributors to subsequent skeletal
abnormalities.
Vascular invasion of the developing skeleton occurs during mid-
gestation. At E14.5, the cartilage primordia of the endochondral
skeleton are surrounded by blood vessels in wild type embryos. By
E15.5, blood vessels have fully penetrated into the primary ossiﬁcation
centers, together with chondroclast/osteoclast recruitment. VEGF is
robustly expressed in the perichondrium and surrounding tissues at
E13.5, which probably stimulates vascular in-growth (Zelzer et al.,
2002). At E17, Sema3A and Neuropilin-1 are expressed by the outer
perichondrium and the hypertrophic chondrocytes within the
primary ossiﬁcation centers of the diaphysis and metaphysis
(Gomez et al., 2005). Thus, plexinD1 is likely to play an important
role in proper blood vessel invasion into the bone; loss of plexinD1 in
the vasculature leads to axial patterning defects. The skeletal
requirement for normal vascularization is well established (Towler,
2007). For example, mice deﬁcient in matrix metalloproteinase-1
display skeletal defects due to deﬁcient microvasculature (Zhou et al.,
2000), and bone-derived hypoxia-inducible factor 1 couples angio-
genesis to osteogenesis (Wang et al., 2007).
We show that plexinD1 is also necessary in postnatal angiogenesis,
which may have important implications for the future analysis
of plexinD1 as a therapeutic target for pro- or anti-angiogenetic
therapies. It remains unclear if PlexinD1 on endothelial cells functions
primarily to mediate attractive or repulsive signals, or both. Indeed,
Sema3E/PlexinD1 signaling in neurons can result in either attraction
or repulsion, depending on the presence or absence of Neuropilin
(Nrp)-1 (Chauvet et al., 2007). PlexinD1 has been detected in tumor
vasculature, and in a number of brain tumors (Roodink et al., 2005).
Putative PlexinD1 ligands, Sema3A and Sema3C, are able to modulate
the invasive and adhesive properties of prostate cancer cells (Herman
andMeadows, 2007). Nrp-1 and -2 are highly expressed by a variety of
tumors (Bielenberg et al., 2006). It is attractive to speculate that
modulation of Sema/Nrp/PlexinD1 signaling may affect tumor
angiogenesis and disease progression in a manner analogous to that
developed for modulation of VEGF signaling (Holash et al., 2002; Pan
et al., 2007). Our demonstration of a role for PlexinD1 in postnatal
retinal vascularity suggests that PlexinD1 may be a viable target for
the modulation of diabetic retinopathy or other retinal vascular
diseases.
Materials and methods
Generation of plexinD1-ﬂox mice
Mouse genomic clones were derived from a 129/Sv genomic library
(Stratagene). A targeting vector was constructed using 1.8 kb XhoI–
SacII region containing 5′ untranslated sequences for the 5′ arm,
2.4 kb SacII–EcoRI region including exon1 ﬂanked by two loxP sites,
and 8.5 kb EcoRI–SalI (derived from phage DNA) region for the 3′ arm.
A frt-neo-frt-loxP cassette was inserted in a SacII site before exon1.
Another loxP was inserted in an EcoRI site after exon1. A linearized
targeting construct was electroporated into 129Sv/Ev derived ES cells.
Cells were selected with G418 and screened by Southern blot analysis
using a 0.8 kb XbaI–XhoI fragment, generating a 12 kbwild-type and a
4 kb mutant band. Another probe outside the 3′ armwas also used to
conﬁrm 3′ homologous recombination. The cells carrying the correct
mutation were injected into C57BL/6J blastocysts. Chimeric offspring
were mated with C57BL/6J mice. Germ-line transmission of themutant allele was determined by Southern blot analysis of genomic
DNA from tails of mice. Heterozygous F1 animals (plexinD1ﬂox/+) were
intercrossed with a FLPe transgenic mouse (Farley et al., 2000) to
delete the neo cassette.
Genotyping
Mice with plexinD1ﬂox, plexinD1ko, Tie2-cre and CMVcreER alleles
were identiﬁed by PCR strategy using the following primers: plex-
inD1ﬂox forward primer: 5′-ACA GGT GTG TGC TCA AGG CCA CCT C-3′;
plexinD1ﬂox reverse primer: 5′-CAG CCC TAT AGT TCT CCA CCA AAG A-
3′). plexinD1ko forward primer1: 5′-GCC AAG TTC TAA TTC CAT CAG
AAG CTG AC-3′; plexinD1ko forward primer2: 5′-TCA CAC CCC CTA TGT
TCT CCA AGC CTC-3′ plexinD1ko reverse primer: 5′-GAT CAC CTG GGT
TTC TAT GAC CTT AGG-3′; Tie2-cre forward primer: 5′-CGC ATA ACC
AGT GAA ACA GCA TTG C-3′ Tie2-cre reverse primer: 5′-CCC TGT GCT
CAG ACA GAA ATG AGA-3′; CMVCreER forward primer (MG1084) 5′-
GCG GTC TGG CAG TAA AAA CTA TC-3′ CMVCreER reverse primer
(MG1085) 5′-GTG AAA CAG CAT TGC TGT CAC TT-3′. All studies
involving animals were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee.
Primary culture of endothelial cells
Primary endothelial cells were harvested from P0 neonates and
selected twice with Dynabeads (Invitrogen, #110-35) conjugated with
endothelial cell surface marker CD31 antibody (BD Pharmingen,
MEC13.3). This protocol wasmodiﬁed from previously publishedwork
(Chittenden et al., 2006; Li et al., 2002). Dynabeads were washed with
PBS/0.1% BSA three times and incubated with CD31 antibody at 4 °C
overnight (antibody:beads=1:50 vol/vol). P0 pups were euthanized
with CO2.. Heart and descending aorta from each pup were dissec-
ted and minced, and incubated in 5 ml sterilized type I collage-
nase (Worthington biochemical corporation, cat#M6B109) solution
(1 mg/ml in PBS) and rotated at 37 °C for 45 min. The tissue was
disassociated, ﬁltered to remove particulates, resuspended in 2 ml
PBS/0.1%BSA, and incubated with 40 μl CD31 antibody-conjugated
Dynabeads at 37 °C for 10 min. The complexes were selected by a
magnet separator, washed with DMEM/20%FBS medium four times
and then plated onto 1% gelatin pre-treated 6-well tissue culture
plates with 2ml complete endothelial cell growthmedium (EBM+20%
FBS+EGM-2 (Clonetics, CC-4176)).
Boyden chamber assay
Primary endothelial cells (passage 3–6) were starved overnight
(EBM2+0.5%FBS) and labeled with 5 μg/ml calcein AM (Molecular
Probes #C3100MP) for 2 h at 37 °C. Labeled cells were resuspended in
cell dissociation solution (GIBCO #13150-016) for 5–10 min and spin
down, resuspended in complete endothelial cell growth medium at a
concentration of 4×105 cells/ml. 250 μl cells were loaded into
uncoated BD Falcon Fluoroblok inserts (BD #351151) (105 cell/well).
Calcein AM emission was measured every hour in a bottom plate
reader to record cell migration.
Mouse aortic ring assay
Mouse aortic ring assay was modiﬁed from previously described
methods (Masson et al., 2002). The thoracic aortas were harvested
from P0 mice and kept in ice-cold sterilized DMEM (GIBCO BRL). The
peri-aortic ﬁbro-adipose tissue was removed, and the aortas were
sliced to 1 mm rings and washed with DMEM. 300 μl matrigel (BD,
CB40234B) was seeded into 12-well plates on ice and allowed to
solidify at 37 °C for 30 min. Four to 6 rings were placed in each well on
the solid matrigel and another 300 μl of liquid matrigel was added on
top of the explants. The matrigel “sandwich” was then incubated at
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(EBM+20%FBS+EGM-2) was added into each well the next morning.
Explants were photographed using a Nikon Eclipse TE2000-U inverted
microscope and an attached digital camera. The length of the
outgrowth was measured using ImageJ software.
In situ hybridization and immunohistochemistry
Embryonic tissue was ﬁxed in 4%PFA for 24 to 48 h followed by
dehydration in ethanol/PBS solutions, xylene treatment and parafﬁn
embedding. Parafﬁn sections (6 μm) were then used for in situ
hybridization and immunohistochemistry. The plexinD1 antisense
riboprobe were derived from EST #AA138454 corresponding to bp
5901–6955 of mouse plexinD1 mRNA (Accession # NM_026376). In
situ probe forwnt2was designed to target exons 3 and 4 of the mouse
wnt2 gene. PAX1 in situ probe was designed to target nt 1781 to 2440
of mouse PAX1 mRNA (GenBank Accession # AK134066). 35S-labeled
antisense riboprobes were synthesized by in vitro run-off transcrip-
tion of linearized plasmids, using SP6, T7 or T3 RNA polymerase, and
35S-UTP.
For immunohistochemistry on parafﬁn sections we used MF-20
antibody (HybridomaBank), von Willebrand Factor (vWF) antibody
(Sigma, F3520), Neuroﬁlament antibody 2H3 (HybridomaBank),
PECAM antibody (PharMingGen, MEC 13.3), tyrosine hydroxylase
(TH) antibody (Chemicom AB152) and smooth muscle actin (SMA)
antibody (Sigma A2547). Runx2 antibody (Sanrz Cruz #M-79) was
used for immunohistochemical staining at a concentration of 1:20.
For whole-mount PECAM staining we used the puriﬁed anti-
mouse CD31 (BD Pharmingen, MEC13.3) antibody, HRP-goat-to-rat
antibody (Abcam, ab6120–250) and the DAB peroxidase substrate kit
(Vector#SK-4100). E11.5 embryos or embryonic hearts were ﬁxed in
4% PFA overnight at 4 °C. Fixed embryos were rinsed in PBT (PBS/0.1%
TWEEN) and dehydrated in methanol/PBT, bleached in 5% H2O2/
methanol, and rehydrated in methanol/PBT. The tissues were then
blocked in 2% milk/PBT for 30 min and incubated with CD31 antibody
(1:500) in 2% milk/PBT at 4 °C overnight, followed secondary antibody
HRP-Goat-anti-Rat IgG staining, and were developed using DAB
substrate kit (VECTOR, SK-4100). Animal and section preparations
were described in the Materials and methods.
RT-PCR
For RT-PCR analysis, mouse tissues were placed in liquid nitrogen
immediately after dissection and stored at −80 °C until use. Total RNA
was isolated using Trizol reagent (Invitrogen). First-strand cDNA was
generated by random heximer priming utilizing the SuperScript III
ﬁrst strand cDNA synthesis system for RT-PCR (Invitrogen). To prevent
trace amount of DNA contamination, RNA samples were treated with
ampliﬁcation grade DNase I (Invitrogen) before reverse transcription.
Of the resulting cDNA, 1.0 μl was used in a subsequent 20 μl
quantitative PCR reaction. All qPCRs were conducted in 384
plates using the 7900HT Sequence Detection System and the results
were analyzed by the SDS2.0 software (Applied Biosystem).
Primers for plexinD1, (D1_F: 5′-TGA ACA CAC TGG CCC ACT ACA
AGA-3′), (D1_R: 5′-TGT CCA AGT CTT TCA CTC TGC CCA-3′).
Skeletal staining
Mouse P0 pups were euthanized and the skin and fat tissue were
removed and then ﬁxed in 90% ethanol. The liver, kidney and gut were
removed prior to staining. Tissue was then placed in 20 ml freshly
prepared Alcian Blue solution (16 ml 100% ethanol, 2 mg Alcian Blue
and 4 ml glacial acetic acid dissolved in 0.8 ml ddH2O) for 3 days at
room temperature, then washed in 70%, 40% and 15% ethanol solution
each for 2–3 h and then in water. The preparation was immersed in
freshly prepared 1% KOH until it became transparent and then AlizarinRed S solution (1% KOH with Alizarin Red S) until the bones were
stained.
Primary osteoblast cultures
P0 pups were sacriﬁced in CO2 followed by decapitation. Calvaria
were surgically removed, excess soft tissue trimmed, and placed in a
sterile 1.5 ml Eppendorf tube with 1 ml of digestion solution [αMEM,
0.1% collagenase (Sigma—type 1A#C9891), 0.2% dispase (Boeringer
Mannheim #165859)] and incubated at 37 °C at 180RMP plate rotator
for 10 min. The calvaria would settle to the bottom of the tube and the
supernatant was discarded. Another 1 ml of digestion solution was
added and rotated at 37 °C for 20–30 min. Supernatant was
centrifuged at 1500 RPM for 5 min at 4 °C and the pelleted cells
were plated in 6-well dishes in culture media (αMEM+10%FBS).
Micro-CT bone imaging and sample preparation
Euthanized animals were perfused via the left ventricle ﬁrst with
2mlof heparinized saline, then 2mlof 2% paraformaldehyde in PBS, and
ﬁnally with 2–4 ml of Microﬁl (Flow Tech, Inc.) using a 21-gauge
butterﬂy needle. The intravascular Microﬁl was allowed to solidify for
4 h and the specimens were then ﬁxed and stored in 10% formalin.
Micro-CT imaging was performed on an eXplore Locus SP specimen
scanner (GE Healthcare, London, Ontario, Canada). Scan protocols used
80 kVp, 80 μA, 250 μm Al ﬁlter, short-scan (Parker) method with 400
views at 0.5° steps,1.7 s exposure time, 2x2 binmode, four averages, and
Feldkamp conebeam ﬁltered back projection reconstruction at either
29×29×29 μm3 or 58×58×58 μm3 voxels. Three-dimensional volume
rendering and multi-planar reformatting were performed using the
OsiriX dicomviewer (www.osirix-viewer.com). Imagingwas performed
at the Small Animal Imaging Facility in the Department of Radiology at
the University of Pennsylvania School of Medicine.
Induction with tamoxifen
Tamoxifen (TM) (Sigma, #T5648) was dissolved in corn oil at a
concentration of 10 mg/ml and administered as described (Hayashi
and McMahon, 2002). For neonatal mice, 50 μl of TM was injected
intraperitoneally at P3 and P4. For adult mice, 4 mg of TM/40 g of body
weight was injected intraperitoneally daily for 5 consecutive days.
Matrigel plug assay
Matrigel plugs were prepared as described (Malinda et al., 1997).
Matrigel (Beckton Dickinson #356231) with PBS or endothelial cell
growth factor (ECGF) was implanted subcutaneously. We use EGM-2
mixture (clonetics, CC-4176) as the supply of ECGF, which contains
Heparin, VEGF, R3-IGF-1 and hEGF. After 7 days the Matrigel plugs
were excised and ﬁxed in 4%PFA for 24 h at room temperature,
embedded in parafﬁn and stained with Masson's Trichrome. Image J
was used to calculate cellularity.
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